- Home
- CRMD vs GOSS Comparison
CRMD vs GOSS Comparison
Compare CRMD & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRMD
- GOSS
- Stock Information
- Founded
- CRMD 2006
- GOSS 2015
- Country
- CRMD United States
- GOSS United States
- Employees
- CRMD N/A
- GOSS N/A
- Industry
- CRMD Biotechnology: Pharmaceutical Preparations
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- CRMD Health Care
- GOSS Health Care
- Exchange
- CRMD Nasdaq
- GOSS Nasdaq
- Market Cap
- CRMD 876.7M
- GOSS 726.8M
- IPO Year
- CRMD 2010
- GOSS 2019
- Fundamental
- Price
- CRMD $9.79
- GOSS $3.06
- Analyst Decision
- CRMD Strong Buy
- GOSS Strong Buy
- Analyst Count
- CRMD 7
- GOSS 6
- Target Price
- CRMD $17.43
- GOSS $8.60
- AVG Volume (30 Days)
- CRMD 3.1M
- GOSS 2.8M
- Earning Date
- CRMD 11-12-2025
- GOSS 11-05-2025
- Dividend Yield
- CRMD N/A
- GOSS N/A
- EPS Growth
- CRMD N/A
- GOSS N/A
- EPS
- CRMD 2.25
- GOSS N/A
- Revenue
- CRMD $214,303,672.00
- GOSS $44,051,000.00
- Revenue This Year
- CRMD $565.64
- GOSS N/A
- Revenue Next Year
- CRMD $46.09
- GOSS $16.11
- P/E Ratio
- CRMD $4.30
- GOSS N/A
- Revenue Growth
- CRMD 1647.67
- GOSS N/A
- 52 Week Low
- CRMD $5.60
- GOSS $0.66
- 52 Week High
- CRMD $17.43
- GOSS $3.60
- Technical
- Relative Strength Index (RSI)
- CRMD 38.57
- GOSS 62.44
- Support Level
- CRMD $9.45
- GOSS $2.93
- Resistance Level
- CRMD $10.40
- GOSS $3.28
- Average True Range (ATR)
- CRMD 0.68
- GOSS 0.20
- MACD
- CRMD -0.14
- GOSS 0.06
- Stochastic Oscillator
- CRMD 13.66
- GOSS 75.35
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.